Dragoneer Exits, Deerfield Increases Stake as Inspire V™ Launches in Singapore

Introduction

Inspire Medical Systems Inc (ticker: INSP) is a publicly traded medical technology company listed on the New York Stock Exchange. Founded in 2007 and headquartered in Golden Valley, Minnesota, Inspire develops neurostimulation solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire® system is the first fully implanted device approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe OSA.

Corporate Structure

As of 2025, Inspire employs between 1,001 and 5,000 people across its Golden Valley headquarters and field operations. The company’s core offering—comprising an implantable stimulator, a handheld remote, and a mobile app—relies on a multidisciplinary workforce of engineers, clinical researchers, regulatory specialists, and sales professionals. Inspire’s leadership team reports regularly to investors through Securities and Exchange Commission filings and investor events.

Neurostimulation by David Matos

Developments and News

• On November 17, 2025, Inspire filed a Form 8-K with the SEC, disclosing operational updates for Q3 and management commentary on FDA lifecycles.
• On November 14, 2025, an amended Schedule 13G/A reported zero shares held by Dragoneer Investment Group, LLC, indicating a full divestment by that investor.
• On November 13, 2025, Deerfield Management Company, L.P. disclosed beneficial ownership of 1,476,303 shares (5.08% of outstanding common stock) under Schedule 13G.
• The Inspire V™ system received commercial approval in Singapore in October 2025, marking its first international launch.
• At the International Surgical Sleep Society and American Academy of Otolaryngology conferences in October 2025, Inspire presented clinical data related to patient comfort settings and treatment satisfaction.

Financial and Strategic Analysis

On November 24, 2025, Inspire shares closed at USD 116.60, with a trading volume of 1,947,027 shares. Key financial metrics (TTM, as of Q3 2025) include:

• Revenue: USD 882.62 million
• Net income: USD 44.56 million (5.05% profit margin)
• Diluted EPS: USD 1.46; P/E ratio: 61.55
• Total cash: USD 322.59 million; debt/equity: 4.89%
• Price/sales: 3.06; price/book: 3.92; EV/EBITDA: 35.90

Yahoo Finance assigns an Investment Rating of “Sell” with a one-year target of USD 106.79 (as of November 21, 2025). Management has indicated a continued investment in research and development (R&D) and provider training to facilitate broader adoption of neurostimulation technology.

Market Position and Industry Context

Inspire operates within the global sleep apnea treatment market, which is significant in scale. Its FDA-approved, fully implanted system differentiates it from external CPAP devices and emerging oral appliances. The regulatory environment for implantable medical devices is stringent. Inspire's proprietary algorithm and long-term clinical data are expected to present challenges for competitors. Key risks include reimbursement dynamics, competition from established respiratory device manufacturers, and ongoing regulatory compliance.

tl;dr

On November 24, 2025, INSP shares closed at USD 116.60 with a volume of approximately 2 million shares. Deerfield Management holds a 5.08% stake, while Dragoneer Investment Group has exited its position. The Inspire V™ system received approval in Singapore in October 2025. The company reported USD 882.62 million in revenue and USD 44.56 million in net income while maintaining USD 322.59 million in cash reserves. The outlook focuses on expanding neurostimulation adoption and scaling international market entry.